$29.04
-0.44-1.49%
At close: Nov 13, 4:00 PM EST
$28.21
-0.83-2.86%
After Hours: Nov 13, 4:41 PM EST
Adaptive Biotechnologies Corp
ADPTNASDAQ
Adaptive Biotechnologies rose 111.8% from $13.71 to $29.04, ahead of the S&P 500's +13.3%. Its worst day was Dec 5 (−15.5%), and its low came Mar 27 at $12.41.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Adaptive Biotechnologies shares rose 14.0%, while the S&P 500 rose 1.0%.
+14.0% · S&P 500 +1.0%
Adaptive Biotechnologies shares fell 15.5%, while the S&P 500 rose 0.2%.
−15.5%, the year's worst day · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today
+15.9%, the year's best day · S&P 500 +0.2%
EPS of $-0.09 beat the $-0.19 estimate on $71.7M revenue (est. $60.9M).
−4.3% · S&P 500 +1.9%
Adaptive Biotechnologies shares fell 12.4%, while the S&P 500 fell 1.5%.
−12.4% · S&P 500 −1.5%
Adaptive Biotechnologies closed at its lowest level of the year, 9.5% below where the year started.
−11.1% · S&P 500 −1.7%
EPS of $-0.13 beat the $-0.16 estimate on $70.9M revenue (est. $61.1M).
+4.7% · S&P 500 +1.4%
Adaptive Biotechnologies shares rose 13.1%, while the S&P 500 rose 0.4%.
+13.1% · S&P 500 +0.4%
EPS of $-0.10 beat the $-0.13 estimate on $71.6M revenue (est. $66.1M).
+7.2% · S&P 500 +1.7%
EPS of $-0.13 missed the $-0.10 estimate on $83.9M revenue (est. $71.6M).
+0.4% · S&P 500 −4.4%
Where it ended: a close of $29.04 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 4, 2027 (EPS est. $-0.04, revenue est. $80.6M).
Nothing in the past 12 months.
All ADPT dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ADPT and SPY from Benzinga historical bars. Not investment advice.
